活体肝移植治疗不可切除结直肠癌肝转移

Living donor liver transplantation for unresectable colorectal cancer liver metastases

    摘要
  • 摘要:
    目的 分析活体肝移植（LDLT）在不可切除的结直肠癌肝转移（CRLM）患者中的应用现状及疗效。
    方法  2名研究者独立地按照系统评价优先报告条目进行文献检索，从Medline（通过PubMed）、Cochrane Library和ClinicalTrials.gov数据库中筛选出报道LDLT治疗不可切除CRLM相关数据的英文文献，分析文献特征及受者结局。
    结果  总共12项研究，6项已发表研究共纳入55例患者，6项研究正在进行中。部分患者可能在LDLT中获益。报道的术后1年总生存率为100%，3年总生存率为100%和71.4%，1年无进展生存率为85.7%和75.1%，3年无进展生存率为68.6%和53.7%。
    结论  LDLT在不可切除CRLM治疗中的前瞻性研究数据有限，其仍处于探索阶段，需要进行前瞻性临床试验进行验证。

     

    Abstract:
    Objective To assess the current status and outcomes of living donor liver transplantation (LDLT) in patients with unresectable colorectal cancer liver metastases (CRLM).
    Methods Two reviewers independently conducted a systematic search of Medline (via PubMed), the Cochrane Library, and ClinicalTrials.gov in accordance with preferred reporting items for systematic reviews guidelines. English-language publications reporting LDLT for unresectable CRLM were identified; study characteristics and recipient outcomes were extracted.
    Results Twelve studies were retrieved, six completed studies enrolling 55 patients and six ongoing trials. Selected patients appeared to derive benefit from LDLT. Reported overall survival was 100% at 1 year and 100%, 71.4% at 3 years. The 1-year progression-free survival was 85.7% and 75.1%, and 3-year progression-free survival was 68.6% and 53.7%.
    Conclusions Prospective data on LDLT for unresectable CRLM remain scarce. The approach is still investigational and warrants validation through prospective clinical trials.

     

    • HTML全文
    • 参考文献(38)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回